Sara Zarnegar-Lumley, MD, MS

Sara Zarnegar-Lumley, MD, MS

Assistant Professor of Pediatrics
Department of Pediatrics
Office Address
Preston Research Building
2220 Pierce Avenue
Room / Suite
397
Nashville
Tennessee
37232-6311
(615) 322-2177

Specialty
Hematology/Oncology
M.D.
Georgetown University, 2011
Residency
Ann and Robert H. Lurie Children's Hospital, 2014
Fellowship 
Memorial Sloan-Kettering Cancer Center, 2017
New York-Presbyterian Hospital, 2017
Bachelor of Arts
The University of Chicago, 2002
M.S.
Georgetown University, 2007

Clinical Interests

Acute lymphoblastic leukemia (ALL), Acute myeloid leukemia (AML), Chronic myeloid leukemia (CML), Langerhans cell histiocytosis (LCH), Hemophagocytic lymphohistiocytosis (HLH), Oncofertility

Research Information

Dr. Zarnegar-Lumley joined the Vanderbilt faculty in February 2018 and specializes in the care of pediatric patients with leukemia, lymphoma, and histiocytic disorders. As a clinical investigator in pediatric hematologic malignancies, she has a particular interest in molecularly-targeted therapeutics in pediatric myeloid malignancies.  She completed a Pediatric Hematology/Oncology fellowship at Memorial Sloan Kettering Cancer Center and Weill Cornell/New York Presbyterian Hospital in New York in 2017. There she conducted bench research focused on pediatric KMT2a-rearranged leukemia including the preclinical experiments of a promising epigenetic therapy that is now in early phase clinical trials for this challenging subset of pediatric leukemia.  She also designed a pediatric clinical trial with translational correlative experiments for another epigenetic based small molecule inhibitor. She is currently a Study Chair of a Children's Oncology Group (COG) group-wide study of a molecularly targeted therapy (IDH2 inhibitor, Enasidenib) for a rare genetic subset of relapsed and refractory pediatric acute myeloid leukemia (AML). This therapeutic model will be increasingly relevant with improving molecular risk stratification of pediatric AML. She is actively involved with the COG Myeloid Disease Committee. She is part of the Myeloid Working Group in the Vanderbilt Ingram Cancer Center and is working to expand the pediatric leukemia biospecimen bank to be used for future research. She is also the institutional principal investigator of three upfront COG pediatric acute lymphoblastic leukemia (ALL) trials that are providing targeted immunotherapy to subsets of patients. She is a member of the American Society of Hematology and an invited member of a focus group to refine treatment guidelines for Adolescent and Young Adults (AYA) with ALL.  Dr. Zarnegar-Lumley is a member of the Histiocyte Society and has an interest in the molecular make-up of and treatment opportunities for pediatric Langerhans Cell Histiocytosis (LCH). She previously reported a novel fusion that was a disease driver in a pediatric patient. She will lead Vanderbilt's participation in the North American Consortium for Histiocytosis (NACHO) in order to provide patients at Vanderbilt the opportunity to participate in treatment trials for LCH and hemophagocytic lymphohistiocytosis (HLH).   Finally, Dr. Zarnegar-Lumley has engaged in patient-focused research with an emphasis on onco-fertility. She is particularly interested in provider communication about the risk of fertility impairment due to cancer and cancer therapies and fertility preservation options. She previously conducted survey-based research of AYA females regarding their recall of and satisfaction with an onco-fertility discussion at the time of cancer diagnosis. She is currently a member of the Pediatric Initiative Network of the Onco-fertility Consortium and has participated in a special Onco-fertility edition of the journal Pediatric Blood & Cancer.

>> View Publications on PubMed